Affiliation:
1. Duke University Division of Infectious Diseases, Durham, North Carolina, USA
2. University of North Carolina Chapel Hill Division of Infectious Diseases, Chapel Hill, North Carolina, USA
Abstract
ABSTRACT
The impact of bacterial species on outcome in bloodstream infections (BSI) is incompletely understood. We evaluated the impact of bacterial species on BSI mortality, with adjustment for patient, bacterial, and treatment factors. From 2002 to 2015, all adult inpatients with monomicrobial BSI caused by
Staphylococcus aureus
or Gram-negative bacteria at Duke University Medical Center were prospectively enrolled. Kaplan-Meier curves and multivariable Cox regression with propensity score models were used to examine species-specific bacterial BSI mortality. Of the 2,659 enrolled patients, 999 (38%) were infected with
S. aureus
, and 1,660 (62%) were infected with Gram-negative bacteria. Among patients with Gram-negative BSI,
Enterobacteriaceae
(81% [1,343/1,660]) were most commonly isolated, followed by non-lactose-fermenting Gram-negative bacteria (16% [262/1,660]). Of the 999
S. aureus
BSI isolates, 507 (51%) were methicillin resistant. Of the 1,660 Gram-negative BSI isolates, 500 (30%) were multidrug resistant. The unadjusted time-to-mortality among patients with Gram-negative BSI was shorter than that of patients with
S. aureus
BSI (
P
= 0.003), due to increased mortality in patients with non-lactose-fermenting Gram-negative BSI generally (
P
< 0.0001) and
Pseudomonas aeruginosa
BSI (
n
= 158) in particular (
P
< 0.0001). After adjustment for patient demographics, medical comorbidities, bacterial antibiotic resistance, timing of appropriate antibiotic therapy, and source control in patients with line-associated BSI,
P. aeruginosa
BSI remained significantly associated with increased mortality (hazard ratio = 1.435; 95% confidence interval = 1.043 to 1.933;
P
= 0.02).
P. aeruginosa
BSI was associated with increased mortality relative to
S. aureus
or other Gram-negative BSI. This effect persisted after adjustment for patient, bacterial, and treatment factors.
Funder
HHS | National Institutes of Health
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology